BMRN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

822.12M

+10.01%

0.926

+0.6%

818.32M

+9.82%

1.264

+11.83%

869.76M

+5.37%

0.916

-36.36%

Estimates Revision

The market is revising Downward the revenue expectations for BioMarin Pharmaceutical Inc. (BMRN) for FY2025, with the revenue forecasts being adjusted by -0.1% over the past three months. During the same period, the stock price has changed by 12.67%.

Revenue Estimates for FY2025

Revise Downward

-0.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.05%

In Past 3 Month

Stock Price

Go Up

+12.67%

In Past 3 Month

18 Analyst Rating

Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.50 USD with a low forecast of 55.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

4 Hold

0 Sell

Strong Buy

Current: 0.000

Low

55.00

Averages

87.50

High

120.00

Current: 0.000

Low

55.00

Averages

87.50

High

120.00

Leerink

Joseph Schwartz

Outperform

Market Perform

downgrade

$17

2025-12-29

Reason

Leerink

Joseph Schwartz

Price Target

$17

2025-12-29

downgrade

Outperform

Market Perform

Reason

Leerink analyst Joseph Schwartz downgraded Amicus (FOLD) to Market Perform from Outperform with a price target of $14.50, down from $17, following the recently announced acquisition by BioMarin (BMRN). The firm views BioMarin is a good strategic fit and thinks it is unlikely that another bid will emerge.

Truist

Joon Lee

Buy

maintain

$80 -> $100

2025-12-23

Reason

Truist

Joon Lee

Price Target

$80 -> $100

2025-12-23

maintain

Buy

Reason

Truist analyst Joon Lee raised the firm's price target on BioMarin (BMRN) to $100 from $80 and keeps a Buy rating on the shares. The company's proposed acquisition of Amicus (FOLD) hits all the right notes based on the following, including two approved rare disease drugs aligns with BioMarin's rare disease focus, the analyst tells investors in a research note. The deal is also accretive within 12 months post close in Q2 and substantially accretive starting 2027 given that Amicus is a profitable biotech, Truist notes, adding that the combination having twice the size of greater geographic reach of BioMarin vs. Amicus could drive continued growth into relatively long exclusivity into 2037.

Oppenheimer

Outperform

initiated

$283

2025-12-23

Reason

Oppenheimer

Price Target

$283

2025-12-23

initiated

Outperform

Reason

Oppenheimer initiated coverage of Spruce Biosciences (SPRB) with an Outperform rating and $283 price target. Further to FDA's confirmation that existing and what the firm views as "compelling" clinical biomarker data could drive accelerated approval, recent Breakthrough Therapy designation bolsters the firm's conviction ahead of next year's anticipated approval for Sanfilippo type B syndrome, the analyst tells investors. The firm, which sees "considerable upside for this underappreciated story," adds that it believes BioMarin (BMRN) would be "a logical acquirer."

H.C. Wainwright

Neutral

maintain

$55 -> $60

2025-12-22

Reason

H.C. Wainwright

Price Target

$55 -> $60

2025-12-22

maintain

Neutral

Reason

H.C. Wainwright raised the firm's price target on BioMarin (BMRN) to $60 from $55 and keeps a Neutral rating on the shares. The firm views the company's acquisition of Amicus (FOLD as a "strategic move that secures long- term durability of cash flows but places the peak sales payoff firmly in the 2030s." The payoff to the Amicus deal is "far away," and until then, Voxzogo remains the focal point of BioMarin shares, the analyst tells investors in a research note.

Citi

Samantha Semenkow

Buy -> Neutral

downgrade

$17

2025-12-21

Reason

Citi

Samantha Semenkow

Price Target

$17

2025-12-21

downgrade

Buy -> Neutral

Reason

Citi analyst Samantha Semenkow downgraded Amicus (FOLD) to Neutral from Buy with a price target of $14.50, down from $17, after BioMarin BMRN) announced it will acquire Amicus for $4.8B or $14.50 per share. Citi sees low potential of another bidder emerging.

Cantor Fitzgerald

Overweight -> Neutral

downgrade

$14.50

2025-12-19

Reason

Cantor Fitzgerald

Price Target

$14.50

2025-12-19

downgrade

Overweight -> Neutral

Reason

Cantor Fitzgerald downgraded Amicus (FOLD) to Neutral from Overweight with a $14.50 price target after BioMarin (BMRN) agreed to acquire the company for $14.50 per share in cash.

Valuation Metrics

The current forward P/E ratio for BioMarin Pharmaceutical Inc (BMRN.O) is 13.45, compared to its 5-year average forward P/E of 39.39. For a more detailed relative valuation and DCF analysis to assess BioMarin Pharmaceutical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

39.39

Current PE

13.45

Overvalued PE

63.84

Undervalued PE

14.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

66.57

Current EV/EBITDA

10.90

Overvalued EV/EBITDA

182.09

Undervalued EV/EBITDA

-48.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.15

Current PS

3.39

Overvalued PS

7.79

Undervalued PS

4.50

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BMRN News & Events

Events Timeline

No data

News

7.5

01-09PRnewswire

Veeva Partners with BioMarin to Enhance Drug Development Efficiency

7.5

01-09PRnewswire

Veeva Partners with BioMarin to Enhance Drug Development Speed and Efficiency

1.0

01-08Newsfilter

BioMarin to Announce Preliminary 2025 Financial Results at J.P. Morgan Conference on January 12

People Also Watch

Frequently Asked Questions

What is BioMarin Pharmaceutical Inc (BMRN) stock price today?

The current price of BMRN is 58.95 USD — it has decreased -2.32 % in the last trading day.

What is BioMarin Pharmaceutical Inc (BMRN)'s business?

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

What is the price predicton of BMRN Stock?

What is BioMarin Pharmaceutical Inc (BMRN)'s revenue for the last quarter?

BioMarin Pharmaceutical Inc revenue for the last quarter amounts to 776.13M USD, increased 4.08 % YoY.

What is BioMarin Pharmaceutical Inc (BMRN)'s earnings per share (EPS) for the last quarter?

BioMarin Pharmaceutical Inc. EPS for the last quarter amounts to -0.16 USD, decreased -129.09 % YoY.

What changes have occurred in the market's expectations for BioMarin Pharmaceutical Inc (BMRN)'s fundamentals?

How many employees does BioMarin Pharmaceutical Inc (BMRN). have?

BioMarin Pharmaceutical Inc (BMRN) has 3040 emplpoyees as of January 10 2026.

What is BioMarin Pharmaceutical Inc (BMRN) market cap?

Today BMRN has the market capitalization of 11.33B USD.